百济神州前三季度净利11.39亿元

Core Insights - The company reported a revenue of 27.595 billion yuan for the first three quarters, representing a year-on-year growth of 44.2% [1] - The net profit attributable to the company was 1.139 billion yuan [1] - In the third quarter, product revenue reached 9.954 billion yuan, compared to 7.079 billion yuan in the same period last year, indicating significant growth driven by self-developed products and licensed products [1] Financial Performance - Total revenue for the first three quarters was 27.595 billion yuan, with a year-on-year increase of 44.2% [1] - Net profit for the same period was reported at 1.139 billion yuan [1] - Third-quarter product revenue was 9.954 billion yuan, up from 7.079 billion yuan year-on-year [1] Product Performance - The growth in product revenue was primarily attributed to the sales increase of self-developed product Baiyueze (Zebutinib capsules) and licensed products, as well as Bai Ze An (Tislelizumab injection) [1]